FDA approves Novartis Kisqali® to reduce risk of recurrence in …
WEB5 days ago · Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. ... News; FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- …
Novartis Kisqali® shows deepening benefit in new analysis, …
WEB6 days ago · Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. ... News; Novartis Kisqali® shows deepening benefit in ...
News - Novartis
WEBNews. Information for journalists including media releases, statements, stories, multimedia resources and more.
Novartis unveils new focused strategy, underpinned by eight …
WEBSep 22, 2022 · Novartis is implementing this strategy with a clear focus on five therapeutic areas for investment - cardiovascular, immunology, neuroscience, solid tumors and hematology.
New Novartis data in relapsing MS reinforce benefits of …
WEB4 days ago · Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. ... News; New Novartis data in relapsing MS reinforce benefits of …
Novartis’ Kisqali gets expanded FDA OK; Mene Pangalos joins …
WEB4 days ago · Today, a brief rundown of news from Novartis and GSK, as well as updates from Omega Funds, Serán Bioscience and Boehringer Ingelheim that you may have missed. The Food and Drug Administration approved expanded use of Novartis ’ breast cancer drug Kisqali, permitting its use in women in early stages of hormone-sensitive, HER-negative disease ...
Novartis Raises Outlook, Plans Buyback of Up to $15 Billion
WEBJul 18, 2023 · Novartis AG raised its profit outlook and announced plans to buy back as much as $15 billion in shares as it prepares to spin off its Sandoz generics unit.
Novartis Eyes Rare Kidney Disease Approvals on Heels of Two ... - BioSpace
WEBMay 28, 2024 · Novartis on Saturday posted two promising Phase III readouts in rare kidney diseases, setting the pharma up for two potential approvals in the space. The company presented these data at the European Renal Association Congress over the weekend. Results from the Phase III ALIGN study showed that at 36 weeks, Novartis’ investigational endothelin ...
Novartis announces new organizational structure to
WEBBasel, April 4, 2022 — Novartis today announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity...
Novartis AG: Hold Rating Justified Amid Kisqali’s Market Potential …
WEB4 days ago · Eric Le Berrigaud’s rating is based on the comprehensive analysis of Novartis AG’s recent developments and market potential for its breast cancer treatment, Kisqali.
Skip to content